"Oxford–AstraZeneca COVID-19 vaccine"

Reported side-effects following Oxford/AstraZeneca COVID-19 vaccine in the north-west province, Iran: A cross-sectional study. While the vaccination was introduced as a promising tool to control the Coronavirus disease 2019 (COVID-19) pandemic, concerns about vaccine-related side effects had grown. Due to the widespread administration of the COVID-19 vaccine worldwide for the first time

Low credibility URL sharing on Twitter during reporting linking rare blood clots with the Oxford/AstraZeneca COVID-19 vaccine. The COVID-19 pandemic was accompanied by an "infodemic" of misinformation. Misleading narratives around the virus, its origin, and treatments have had serious implications for public health. In March 2021, concerns were raised about links between the Oxford/AstraZeneca

A case of acute tubulointerstitial nephritis following administration of the Oxford-AstraZeneca COVID-19 vaccine: a case report. More than 4 billion doses of the Coronavirus disease (COVID-19) vaccine have been administered worldwide but the relationship between the different vaccines and the development of renal disease is unknown. We present a case of tubulointerstitial nephritis following administration of the Oxford-AstraZeneca COVID-19 vaccine. A previously fit and well 51-year-old female presented on 27th May 2021 with a one-month history of weight loss, fatigue, nausea, and a metallic taste. She had an acute kidney injury with a creatinine of 484 umol/L. She was on no regular medications and denied taking any over-the-counter or alternative medicines. She had received her first dose

A prospective cohort study protocol: monitoring and surveillance of adverse events following heterologous booster doses of Oxford AstraZeneca COVID-19 vaccine in previous recipients of two doses of Sinopharm or Sputnik V vaccines in Iran. Regarding the paucity of evidence on the side effects of the booster dose of Oxford AstraZeneca vaccine in vaccinated people with Sinopharm or Sputnik V, we

Immunogenicity of Oxford-AstraZeneca COVID-19 Vaccine in Vietnamese Health-Care Workers. We studied the immunogenicity of the Oxford-AstraZeneca vaccine in health-care workers of a major infectious diseases hospital in Vietnam. We measured neutralizing antibodies before and 14 days after each dose, and at day 28 and month 3 after dose 1. A total of 554 workers (136 men and 418 women; age range were not observable. In addition, the proportion of study participants with detectable neutralizing antibodies increased from 70.2% (73 of 104) before dose 2 (week 6, after dose 1) to 98.1% (102 of 104) 14 days later. At month 3, neutralizing antibodies decreased and 94.7% (89 of 94) of the study participants remained seropositive. The Oxford-AstraZeneca COVID-19 vaccine is immunogenic in Vietnamese

Linear IgA bullous dermatosis following Oxford AstraZeneca COVID-19 vaccine. A case of linear IgA bullous dermatosis developing 3 days after the second dose of Oxford AstraZeneca COVID-19 vaccine in an adult patient, suggesting a possible causal association. It is worth keeping in mind that COVID-19 vaccination could induce immune-mediated bullous disease in susceptible people.

De novo generalized pustular psoriasis following Oxford-AstraZeneca COVID-19 vaccine. We present an interesting and novel case of a de novo generalized pustular psoriasis following administration of first dose of Oxford-AstraZeneca COVID-19 vaccine in a patient with no pre-existing psoriasis or any previous dermatological issue.

Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups. Background COVID-19 vaccines approved in the UK are highly effective in general population cohorts, however, data on effectiveness amongst individuals with clinical conditions that place them at increased risk of severe disease are limited. Methods We used GP

Comparing the longer-term effectiveness of a single dose of the Pfizer-BioNTech and Oxford-AstraZeneca COVID-19 vaccines across the age spectrum. A single dose strategy may be adequate to confer population level immunity and protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, especially in low- and middle-income countries where vaccine supply remains

Effectiveness of the Oxford-AstraZeneca COVID-19 Vaccine as a 2nd Booster, the REFORCO-Brazil Study This study will address specific questions concerning the additional protection of the AZ COVID-19 vaccine as a second booster dose in preventing severe COVID-19 outcomes (hospitalisation, ICU admission etc) and will provide data to inform COVID-19 vaccine booster dose recommendations. In Brazil

Oxford/AstraZeneca COVID-19 Vaccine Effectiveness in England This is a retrospective cohort study to assess the real world effectiveness of the Oxford/AstraZeneca COVID-19 vaccine in England. The study is using linkage of the English national databases on COVID-19 vaccination, testing, medical records, hospitalization, and death. The United Kingdom (UK) is one of the first countries /AstraZeneca vaccine started in early January 2021. This study is to primarily assess the effectiveness of the Oxford/AstraZeneca COVID-19 vaccine. Given the known high efficacy of the mRNA vaccines in randomized controlled trials (RCTs) and real-world evidence studies, the study aims also to evaluate the vaccine effectiveness (VE) of other COVID-19 vaccines as a validation of the study's methods. On 16

Neurobiol 2021;47:17–25. 10. Østergaard SD, Schmidt M, Horváth-Puhó E, Thomsen RW, Sørensen HT. Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence? Lancet 2021;397:1441–1443. 11. Dawson TP, Neal JW, Llewellyn L, Thomas C. Neuropathology Techniques. London, UK: Hodder Arnold, 2003. 12. Osborn M, Howard M, Morley S, McCarthy H . Guidelines on Autopsy Practice

and expanded indications for COVID-19 • Pfizer-BioNTech COVID-19 vaccine: What you should know • Moderna COVID-19 vaccine: What you should know V-4.0 APRIL 6, 2021 2 • Vaxzevria (Oxford-AstraZeneca) COVID-19 vaccine: What you should know • Janssen COVID-19 vaccine: What you should know Summary of efficacy and safety vaccines approved by Health Canada (see summary table on Page 8) Pfizer-BioNTech and Moderna COVID-19 vaccines: The first 2 COVID-19 vaccines to receive Health Canada approval for use (Pfizer-BioNTech10 and Moderna11) have shown over 80% efficacy for preventing symptomatic and severe disease. The duration of follow up has been limited to 2-4 months. Vaxzevria (Oxford-AstraZeneca) COVID-19 vaccine: The approval for use of the Vaxzevria (Oxford-AstraZeneca)12COVID-19 vaccine in Canada

vaccines: The first 2 COVID-19 vaccines to receive Health Canada approval for use (Pfizer-BioNTech10 and Moderna11) have shown over 80% efficacy for preventing symptomatic and severe disease. The duration of follow up has been limited to 2-4 months. Oxford-AstraZeneca COVID-19 vaccine: The recent approval for use of the Oxford-AstraZeneca12COVID-19 vaccine in Canada has shown an effectiveness contraindications, especially in those at highest risk of severe illness and death and highest risk of exposure to COVID-19 who are prioritized for early COVID-19 immunization. b. In the context of limited vaccine supply, Oxford-AstraZeneca COVID-19 vaccine may be offered to individuals 18 years of age and older without contraindications if: i. the advantages of earlier vaccination outweigh the limitations

you should know • Oxford-AstraZeneca COVID-19 vaccine: What you should know • Janssen COVID-19 vaccine: What you should know Prioritization of Canadians with lung disease in the vaccination rollout The COVID-19 Respiratory Roundtable led by the CTS issued a joint statement in January urging the federal, provincial and territorial governments to prioritize people living with lung disease who in Appendix A and Appendix B of the PHAC-NACI Recommendations on the use of COVID-19 vaccines report published on September 28, 2021. The authorized mRNA vaccines are safe and efficacious in those with one or more comorbidities (e.g., body mass index ≥30 kg/m2, chronic pulmonary disease, diabetes mellitus, cardiac disease). V-8.0 DECEMBER 2021 3 Oxford-AstraZeneca COVID-19 vaccine The approval for use

on the Oxford / AstraZeneca Covid-19 Vaccine * Position Statement on the Moderna Covid-19 Vaccine * Group Letter: Prioritising Vaccination * Request A Speaker * Our Projects * BIMA Students (sBIMA) * Islamic Prayers – Guidance for NHS Staff and Managers * Conference 2020 * Poster Presentations * Dress Code * Modest Medical Wear Catalogue * HBBE Research in the BMJ * Muslim Mental Health in the pandemic * Coronavirus self-care * Events * COVID-19 Vaccine Hub * Fasting & COVID Vaccinations * Answering The Myths * Webinars * All Statements * Fasting & Lateral flow / PCR * Ramadan Safety Guidance * Position Statement on the Pfizer/BioNTech Covid-19 Vaccine * Position Statement on the Oxford / AstraZeneca Covid-19 Vaccine * Position

Association of AZD1222 and BNT162b2 COVID-19 Vaccination With Thromboembolic and Thrombocytopenic Events in Frontline Personnel : A Retrospective Cohort Study. In March 2021, several European countries suspended the use of the AZD1222 (Oxford-AstraZeneca) COVID-19 vaccine because of thromboembolic safety concerns. Reports from Norway and Germany subsequently described patients with venous